Compare · PRKS vs SLNO
PRKS vs SLNO
Side-by-side comparison of United Parks & Resorts Inc. (PRKS) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRKS and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 1.4x PRKS ($1.98B).
- PRKS has been more active in the news (4 items in the past 4 weeks vs 1 for SLNO).
- SLNO has more recent analyst coverage (12 ratings vs 8 for PRKS).
- Company
- United Parks & Resorts Inc.
- Soleno Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.98B
- $2.76B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- 2014
- News (4w)
- 4
- 1
- Recent ratings
- 8
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest PRKS
- Chief Commercial Officer Finazzo Christopher L. sold $292,692 worth of shares (6,622 units at $44.20), decreasing direct ownership by 5% to 123,663 units (SEC Form 4)
- SEC Form 10-Q filed by United Parks & Resorts Inc.
- United Parks & Resorts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- United Parks & Resorts Inc. Reports Second Quarter and First Six Months 2026 Results
- BUSCH GARDENS TO BRING "ANACONDA" TO HOWL-O-SCREAM THIS FALL
- SEAWORLD TO BRING HORROR FRANCHISE "I KNOW WHAT YOU DID LAST SUMMER" TO HOWL-O-SCREAM THIS FALL
- BUSCH GARDENS TAMPA BAY OPENS WORLD-CLASS LION & HYENA RIDGE AS PART OF $200 MILLION PARK TRANSFORMATION
- UNITED PARKS & RESORTS INC. ANNOUNCES SECOND QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION
- Northcoast initiated coverage on United Parks & Resorts Inc.
- Large owner Hill Path Capital Partners Co-Investment S Lp was granted 1,821 shares (SEC Form 4)
Latest SLNO
- Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)